Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

@article{Huang2012Interleukin28BGV,
  title={Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.},
  author={Chung-Feng Huang and Jee-Fu Huang and Jeng-Fu Yang and M. -J. Hsieh and Z. Y. Lin and Shinn-Cherng Chen and L Y Wang and S. H. Juo and K Chen and W P Chuang and Hsing-Tao Kuo and C. Y. Dai and Ming-Lung Yu},
  journal={Journal of hepatology},
  year={2012},
  volume={56 1},
  pages={34-40}
}
BACKGROUND & AIMS A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. METHODS Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. RESULTS… CONTINUE READING